EcoDrugPlus

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSFCAG00000004983
Gene Symbol: HTR3A
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSFCAG00000004982
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 3e

Ensembl ID : ENSFCAG00000007786
Gene Symbol: HTR3E
5 Cross references
38 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSFCAG00000009931
Gene Symbol: HTR4
5 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSFCAG00000043931
Gene Symbol: HTR5A
5 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSFCAG00000008544
Gene Symbol: HTR7
5 Cross references
221 Possible Orthologues:

60s Ribosomal Protein L21

Ensembl ID : ENSFCAG00000025637
Gene Symbol: LOC101092708
4 Cross references
152 Possible Orthologues:

60s Ribosomal Protein L30-Like

Ensembl ID : ENSFCAG00000048779
Gene Symbol: LOC101080444
4 Cross references
228 Possible Orthologues:

60s Ribosomal Protein L39-Like

Ensembl ID : ENSFCAG00000008251
Gene Symbol: LOC123379197
4 Cross references
178 Possible Orthologues:

60s Ribosomal Protein L39-Like

Ensembl ID : ENSFCAG00000032162
Gene Symbol: LOC111556218
4 Cross references
177 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSFCAG00000025248
Gene Symbol: ARAF
5 Cross references
192 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSFCAG00000005115
Gene Symbol: ABL1
5 Cross references
204 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).